Published in PLoS One on January 18, 2012
Key role of CRF in the skin stress response system. Endocr Rev (2013) 1.77
Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol (2013) 1.71
The relationship between nutrition and prostate cancer: is more always better? Eur Urol (2012) 1.66
Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int (2014) 1.58
The fat side of prostate cancer. Biochim Biophys Acta (2013) 1.46
Cholesterol and prostate cancer. Curr Opin Pharmacol (2012) 1.28
The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol (2013) 1.11
Lipids and prostate cancer. Prostaglandins Other Lipid Mediat (2012) 1.01
Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care (2013) 1.00
New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98
Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med (2015) 0.98
Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer (2015) 0.96
Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev (2014) 0.92
Steroid hormone synthetic pathways in prostate cancer. Transl Androl Urol (2013) 0.89
Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am J Pathol (2014) 0.87
Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol (2015) 0.84
The response of the prostate to circulating cholesterol: activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network. PLoS One (2012) 0.84
Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res (2014) 0.83
SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer. Mol Endocrinol (2013) 0.83
Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1. Oncotarget (2015) 0.83
Apolipoprotein E gene polymorphism influences aggressive behavior in prostate cancer cells by deregulating cholesterol homeostasis. Int J Oncol (2013) 0.82
LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly. Am J Cancer Res (2013) 0.80
The emerging role of obesity, diet and lipid metabolism in prostate cancer. Future Oncol (2016) 0.79
Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts. Prostate Cancer Prostatic Dis (2015) 0.78
Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev (2016) 0.77
Progress in Understanding What Is Being Statin(ed) in Prostate Cancer. JAMA Oncol (2015) 0.77
Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men. Lipids Health Dis (2015) 0.76
Identification of CETP as a molecular target for estrogen positive breast cancer cell death by cholesterol depleting agents. Genes Cancer (2016) 0.75
High incidence of prostate cancer metastasis in Afro-Brazilian men with low educational levels: a retrospective observational study. BMC Public Health (2013) 0.75
Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer. Mol Cancer Res (2016) 0.75
Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins. Prostate Int (2016) 0.75
Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nat Rev Urol (2016) 0.75
Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. Prostate Int (2014) 0.75
Metabolic profiling of cholesterol and sex steroid hormones to monitor urological diseases. Endocr Relat Cancer (2016) 0.75
Words of wisdom. Re: Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. Eur Urol (2013) 0.75
AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers (Basel) (2017) 0.75
Mechanisms of Androgen-Independent Prostate Cancer. EJIFCC (2014) 0.75
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Lipid rafts as a membrane-organizing principle. Science (2010) 13.48
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
Statins and cancer risk: a meta-analysis. JAMA (2006) 6.28
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science (2004) 6.19
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res (2005) 5.04
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol (2010) 4.39
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1998) 4.18
Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst (2006) 3.96
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem (2004) 3.51
Cancer risk among statin users: a population-based cohort study. Int J Cancer (2005) 3.50
Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem (2004) 3.27
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol (2010) 3.08
The risk of cancer in users of statins. J Clin Oncol (2004) 3.01
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res (1999) 2.96
Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest (2005) 2.89
Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res (2002) 2.46
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res (2004) 2.15
Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res (2002) 2.11
Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol (2007) 2.09
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 2.05
Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer (2007) 2.00
Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev (2007) 1.94
Cholesterol and prostate cancer. J Cell Biochem (2004) 1.92
Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev (2007) 1.91
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res (1996) 1.82
Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab (2008) 1.78
Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab (2008) 1.74
Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer (2008) 1.70
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J (2003) 1.68
Adrenal glands of mouse and rat do not synthesize androgens. Life Sci (1992) 1.64
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res (1997) 1.62
A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control (2001) 1.62
Dietary fat and prostate cancer: current status. J Natl Cancer Inst (1999) 1.61
Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer (2010) 1.59
The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res (2004) 1.58
Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol (2008) 1.57
CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol (2008) 1.49
Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst (2011) 1.49
Dietary patterns and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev (2006) 1.47
Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. J Androl (2007) 1.45
Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control (2009) 1.40
Adrenal androgens and intracrinology. Semin Reprod Med (2004) 1.35
Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer (2003) 1.34
Dietary patterns and risk of prostate cancer in Ontario, Canada. Int J Cancer (2005) 1.26
Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother (2008) 1.19
Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol (2009) 1.18
Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer (2009) 1.16
Steroid levels in cancer of the prostate--markers of tumor differentiation and adequacy of anti-androgen therapy. Prog Clin Biol Res (1979) 1.14
Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study. Cancer Causes Control (2010) 1.12
Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res (2005) 1.10
Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev (2007) 1.08
Prostatic cholesterol metabolism: regulation and alteration. Prog Clin Biol Res (1981) 1.04
Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int (2007) 0.87
Steroid levels in cancer of the prostate--markers of tumour differentiation and adequacy of anti-androgen therapy. J Steroid Biochem (1979) 0.87
Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged? Can J Urol (2008) 0.85
Effectiveness of ezetimibe in clinical practice. Am J Cardiol (2004) 0.83
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest (2005) 2.89
Single photon-emission computed tomography. J Nucl Cardiol (2010) 2.57
Gonadal development of larval male Xenopus laevis exposed to atrazine in outdoor microcosms. Environ Sci Technol (2005) 2.24
Proteome scale characterization of human S-acylated proteins in lipid raft-enriched and non-raft membranes. Mol Cell Proteomics (2009) 2.16
Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res (2002) 2.11
Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res (2009) 2.07
Ontario multidetector computed tomographic coronary angiography study: field evaluation of diagnostic accuracy. Arch Intern Med (2011) 1.97
Cholesterol and prostate cancer. J Cell Biochem (2004) 1.92
Biological monitoring of polyfluoroalkyl substances: A review. Environ Sci Technol (2006) 1.91
An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle (2009) 1.88
Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab (2008) 1.74
The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J (2007) 1.69
Signaling through PI3K/Akt mediates stretch and PDGF-BB-dependent DNA synthesis in bladder smooth muscle cells. J Urol (2003) 1.65
Collection of airborne fluorinated organics and analysis by gas chromatography/chemical ionization mass spectrometry. Anal Chem (2002) 1.62
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol (2012) 1.60
Bioconcentration and tissue distribution of perfluorinated acids in rainbow trout (Oncorhynchus mykiss). Environ Toxicol Chem (2003) 1.56
The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle (2012) 1.56
Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene. J Bone Miner Res (2007) 1.56
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev (2011) 1.51
Atrazine does not affect algal biomass or snail populations in microcosm communities at environmentally relevant concentrations. Environ Toxicol Chem (2011) 1.47
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res (2006) 1.47
Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res (2007) 1.45
The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care (2006) 1.43
Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review. Arch Intern Med (2007) 1.38
Dietary accumulation of perfluorinated acids in juvenile rainbow trout (Oncorhynchus mykiss). Environ Toxicol Chem (2003) 1.37
Is atrazine a potent endocrine disruptor chemical? Environ Sci Technol (2009) 1.35
Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res (2005) 1.31
Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. Lab Invest (2002) 1.30
Cholesterol and prostate cancer. Curr Opin Pharmacol (2012) 1.28
Biotransformation of polychlorinated biphenyls (PCBs) and bioformation of hydroxylated PCBs in fish. Aquat Toxicol (2006) 1.23
Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem (2007) 1.23
Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle (2008) 1.20
The zinc finger protein ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer. Mol Endocrinol (2007) 1.20
MEK4 function, genistein treatment, and invasion of human prostate cancer cells. J Natl Cancer Inst (2009) 1.20
Calcium regulates the PI3K-Akt pathway in stretched osteoblasts. FEBS Lett (2003) 1.19
Optimizing sample handling for urinary proteomics. J Proteome Res (2008) 1.18
Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol (2009) 1.18
Mechanical stretch is a highly selective regulator of gene expression in human bladder smooth muscle cells. Physiol Genomics (2004) 1.17
A quantitative proteomic analysis of growth factor-induced compositional changes in lipid rafts of human smooth muscle cells. Proteomics (2005) 1.15
Proteomic analysis of palmitoylated platelet proteins. Blood (2011) 1.14
Response of larval Xenopus laevis to atrazine: assessment of growth, metamorphosis, and gonadal and laryngeal morphology. Environ Toxicol Chem (2003) 1.14
p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells. FEBS Lett (2007) 1.14
The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. Cancer Res (2007) 1.13
The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am (2011) 1.13
Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle (2013) 1.12
Environmental effects of ozone depletion and its interactions with climate change: progress report, 2009. Photochem Photobiol Sci (2010) 1.11
An hTERT-immortalized human urothelial cell line that responds to anti-proliferative factor. In Vitro Cell Dev Biol Anim (2010) 1.10
Spatial distribution of polybrominated diphenyl ethers and polybrominated biphenyls in lake trout from the Laurentian Great Lakes. Chemosphere (2002) 1.10
Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev (2007) 1.08
Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo) (2006) 1.07
Synergy in microcosms with environmentally realistic concentrations of prochloraz and esfenvalerate. Aquat Toxicol (2010) 1.07
Caveolin-1alpha and -1beta perform nonredundant roles in early vertebrate development. Am J Pathol (2006) 1.06
Synergy between prochloraz and esfenvalerate in Daphnia magna from acute and subchronic exposures in the laboratory and microcosms. Aquat Toxicol (2011) 1.05
Aquatic ecotoxicology of fluoxetine. Toxicol Lett (2003) 1.04
Trafficking of nuclear heparin-binding epidermal growth factor-like growth factor into an epidermal growth factor receptor-dependent autocrine loop in response to oxidative stress. Cancer Res (2005) 1.04
Reversible regional wall motion abnormalities on exercise technetium-99m-gated cardiac single photon emission computed tomography predict high-grade angiographic stenoses. J Am Coll Cardiol (2002) 1.03
MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One (2013) 1.03
Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res (2009) 1.02
Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori (2008) 1.02
Effects of atrazine on metamorphosis, growth, laryngeal and gonadal development, aromatase activity, and sex steroid concentrations in Xenopus laevis. Ecotoxicol Environ Saf (2005) 1.02
Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res (2002) 1.02
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res (2007) 1.01
Proteomic approaches to the analysis of multiprotein signaling complexes. Proteomics (2008) 1.01
DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med (2012) 1.01
A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. Cancer Res (2003) 1.00
Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. Steroids (2006) 1.00
Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology (2003) 1.00
Acrolein induces cyclooxygenase-2 and prostaglandin production in human umbilical vein endothelial cells: roles of p38 MAP kinase. Arterioscler Thromb Vasc Biol (2007) 0.99
Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul Toxicol Pharmacol (2004) 0.98
VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation. Am J Physiol Renal Physiol (2008) 0.98
A protocol for conducting 7-day daily renewal tests with Lemna gibba. Nat Protoc (2007) 0.98
Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology (2002) 0.97
Platelet derived growth factor-BB is a potent mitogen for rat ureteral and human bladder smooth muscle cells: dependence on lipid rafts for cell signaling. J Urol (2003) 0.96
MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling. Cancer Res (2011) 0.95
Antiproliferative factor signaling and interstitial cystitis/painful bladder syndrome. Int Neurourol J (2011) 0.94
Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. BMC Cancer (2008) 0.94
Quantitative proteomics identifies a beta-catenin network as an element of the signaling response to Frizzled-8 protein-related antiproliferative factor. Mol Cell Proteomics (2011) 0.94
Plasma sex steroid concentrations and gonadal aromatase activities in African clawed frogs (Xenopus laevis) from South Africa. Environ Toxicol Chem (2004) 0.93
RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer (2014) 0.93
Plasma concentrations of estradiol and testosterone, gonadal aromatase activity and ultrastructure of the testis in Xenopus laevis exposed to estradiol or atrazine. Aquat Toxicol (2005) 0.93
Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. Proteomics (2013) 0.93
Effects of a mixture of tetracyclines to Lemna gibba and Myriophyllum sibiricum evaluated in aquatic microcosms. Environ Pollut (2005) 0.92
Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther (2007) 0.92